Stoke Therapeutics Q3 revenue beats analyst expectations on Biogen, Acadia collaborations
STOK•Stoke Therapeutics reported Q3 revenue of $11.26 million, beating the $8.18 million analyst estimate, while its net loss was $73.64 million. The company expects its cash to fund operations into early 2028.
1. Quarterly results and outlook
Q3 revenue was driven by fulfillment of collaboration and licensing agreements with Acadia and Biogen. The company reported a $1.08 loss per share and $88.57 million in operating expenses, and said it expects Phase 3 EMPEROR data in Q3 2027 and a U.S. NDA submission in the second half of 2027.
